

May 16, 2022

Yusheng Han  
Chief Executive Officer  
Burning Rock Biotech Ltd  
No. 5 Xingdao Ring Road North  
International Bio Island  
Guangzhou, 510005 The People's Republic of China

Biotech Ltd  
Statement on Form F-3  
2022

Re: Burning Rock  
Registration  
Filed April 29,  
File No. 333-264577

Dear Mr. Han:

We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Registration Statement on Form F-3 filed April 29, 2022

Cover page

1. We note your disclosure that you are not a Chinese operating company but a holding company incorporated in the Cayman Islands and that you conduct operations primarily through your subsidiaries and through contractual arrangements with the variable interest entity or VIE and its subsidiaries. You state that these contractual arrangements enable you to exercise effective control of the VIE. You also state that you are the primary beneficiary of the VIE. Explain whether the VIE structure is used to provide investors with exposure to foreign investment in China-based companies where Chinese law prohibits direct foreign investment in the operating companies.

Yusheng Han  
FirstName LastName Yusheng Han  
Burning Rock Biotech Ltd  
Company  
May Name Burning Rock Biotech Ltd  
16, 2022

May 16,  
Page 2 2022 Page 2  
FirstName LastName

2. Provide a description of how cash is transferred through your organization and disclose your intentions to distribute earnings or settle amounts owed under the VIE agreements. Provide cross-references to the condensed consolidating schedule and the consolidated financial statements. In addition, please add disclosure discussing: (i) restrictions on currency exchanges in China may limit your ability to

freely convert RMB  
to fund any future business activities outside China or other payments  
in U.S. dollars and  
(ii) capital controls the Chinese government imposes may limit your  
ability to use capital  
from your subsidiaries located in China for business purposes outside  
of China.

3. We note your disclosure that your independent registered public  
accounting firm is not  
currently inspected by the PCAOB. We note also that you are named on  
the list of  
Commission Identified Issuers available on our website at  
<https://www.sec.gov/hfcaa>.  
Please revise to provide related disclosure on the cover page, in the  
summary and in the  
Risk Factors section.  
About this Prospectus, page 1

4. Please revise the definition of "China" or "PRC" so that it includes  
Hong Kong and  
Macau.  
Prospectus Summary, page 8

5. We note your disclosure referencing your contractual agreements,  
including the exclusive  
business cooperation agreement, among others. Please ensure you  
describe all contracts  
and arrangements through which you claim to have economic rights and  
exercise control  
that results in consolidation of the VIE's operations and financial  
results into your  
financial statements. Identify clearly the entity in which investors  
are purchasing their  
interest and the entity(ies) in which the company's operations are  
conducted. Describe the  
relevant contractual agreements between the entities and how this type  
of corporate  
structure may affect investors and the value of their investment,  
including how and why  
the contractual arrangements may be less effective than direct  
ownership and that the  
company may incur substantial costs to enforce the terms of the  
arrangements. Disclose  
the uncertainties regarding the status of the rights of the Cayman  
Islands holding company  
with respect to its contractual arrangements with the VIE, its  
founders and owners, and the  
challenges the company may face enforcing these contractual agreements  
due to legal  
uncertainties and jurisdictional limits.

6. We note your disclosure that the Cayman Islands holding company  
controls and receives  
the economic benefits of the VIE's business operations through  
contractual agreements  
between the VIE and your Wholly Foreign-Owned Enterprise (WFOE). We  
also note your  
disclosure that the Cayman Islands holding company is the primary  
beneficiary of the  
VIE. However, neither the investors in the holding company nor the  
holding company  
itself have an equity ownership in, direct foreign investment in, or  
control of, through such  
ownership or investment, the VIE. Accordingly, please refrain from  
implying that the  
contractual agreements are equivalent to equity ownership in the  
business of the VIE. Any

Yusheng Han  
FirstName LastNameYusheng Han  
Burning Rock Biotech Ltd  
Comapany  
May NameBurning Rock Biotech Ltd  
16, 2022

May 16,  
Page 3 2022 Page 3

FirstName LastName

references to control or benefits that accrue to you because of the  
VIE should be limited to  
a clear description of the conditions you have satisfied for  
consolidation of the VIE under  
U.S. GAAP. Additionally, your disclosure should clarify that you are  
the primary

beneficiary of the VIE for accounting purposes. Please also disclose, if true, that the VIE agreements have not been tested in a court of law.

7. In your summary of risk factors, disclose the risks that your corporate structure and being based in or having the majority of the company's operations in China poses to investors. In particular, describe the significant regulatory, liquidity, and enforcement risks with cross-references to the more detailed discussion of these risks in the prospectus. For example, specifically discuss risks arising from the legal system in China, including risks and uncertainties regarding the enforcement of laws and that rules and regulations in China can change quickly with little advance notice; and the risk that the Chinese government may intervene or influence your operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in your operations and/or the value of the securities you are registering for sale. Acknowledge any risks that any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.

For each summary risk factor related to doing business in China, please add a cross-reference to the more detailed discussion in the corresponding risk factor in the Risk Factors section.

8. Disclose each permission or approval that you, your subsidiaries, or the VIEs are required to obtain from Chinese authorities to operate your business and to offer the securities being registered to foreign investors. State whether you, your subsidiaries, or VIEs are covered by permissions requirements from the China Securities Regulatory Commission (CSRC), Cyberspace Administration of China (CAC) or any other governmental agency that is required to approve the VIE's operations, and state affirmatively whether you have received all requisite permissions or approvals and whether any permissions or approvals have been denied. Please also describe the consequences to you and your investors if you, your subsidiaries, or the VIEs: (i) do not receive or maintain such permissions or approvals, (ii) inadvertently conclude that such permissions or approvals are not required, or (iii) applicable laws, regulations, or interpretations change and you are required to obtain such permissions or approvals in the future.

9. Provide a clear description of how cash is transferred through your organization. Disclose your intentions to distribute earnings or settle amounts owed under the VIE agreements. Quantify any cash flows and transfers of other assets by type that have occurred between the holding company, its subsidiaries, and the consolidated VIEs, and direction of transfer.

Quantify any dividends or distributions that a subsidiary or consolidated VIE have made

Yusheng Han  
FirstName LastNameYusheng Han  
Burning Rock Biotech Ltd  
Comapany  
May NameBurning Rock Biotech Ltd

16, 2022

to the holding company and which entity made such transfer, and their tax consequences.

Similarly quantify dividends or distributions made to U.S. investors, the source, and their

tax consequences. Your disclosure should make clear if no transfers, dividends, or

distributions have been made to date. Describe any restrictions on foreign exchange and

your ability to transfer cash between entities, across borders, and to U.S. investors.

Describe any restrictions and limitations on your ability to distribute earnings from the

company, including your subsidiaries and/or the consolidated VIEs, to the parent company

and U.S. investors as well as the ability to settle amounts owed under the VIE agreements.

Please also disclose if you have specific cash management policies and procedures in

place that dictate how funds are transferred through your organization and if applicable,

describe these policies and procedures.

10. Disclose that trading in your securities may be prohibited under the Holding Foreign

Companies Accountable Act if the PCAOB determines that it cannot inspect or investigate

completely your auditor, and that as a result an exchange may determine to delist your

securities. Disclose whether your auditor is subject to the determinations announced by

the PCAOB on December 16, 2021.

Risk Factors

Risks Relating to Our Corporate Structure, page 11

11. Revise your risk factors to acknowledge that if the PRC government determines that the

contractual arrangements constituting part of the VIE structure do not comply with PRC

regulations, or if these regulations change or are interpreted differently in the future, the

securities you are registering may decline in value or become worthless if the

determinations, changes, or interpretations result in your inability to assert contractual

control over the assets of your PRC subsidiaries or the VIEs that conduct all or

substantially all of your operations.

Risks Relating to Doing Business in the PRC, page 12

12. We note your disclosure that the cybersecurity laws and regulations have not directly

affected your business and operations and that you have not been involved in any

investigations on cybersecurity review made by the CAC on such basis.

Please revise your

disclosure to explain how this oversight impacts your business and your offering and to

what extent you believe that you are compliant with the regulations or policies that have

been issued by the CAC to date.

We remind you that the company and its management are responsible for the accuracy

and adequacy of their disclosures, notwithstanding any review, comments, action or absence of

action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate

time for us to review any amendment prior to the requested effective date of the registration

statement.

Yusheng Han

Burning Rock Biotech Ltd

May 16, 2022

Page 5

Please contact Christine Westbrook at 202-551-5019 or Celeste Murphy at 202-551-3257 with any questions.

FirstName LastNameYusheng Han

Sincerely,

Finance

Division of Corporation

Comapany NameBurning Rock Biotech Ltd

Office of Life Sciences

May 16, 2022 Page 5

cc: Shuang Zhao, Esq.

FirstName LastName